Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00142168
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-02-08
- Target Recruit Count
- 8
- Registration Number
- NCT00143065
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Steven P. Treon, MD, PhD
- Target Recruit Count
- 25
- Registration Number
- NCT00142116
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Primary Rituximab and Maintenance
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 1217
- Registration Number
- NCT00140582
- Locations
- 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷Hématologie CHU Purpan, Toulouse, France
🇧🇪Université de Gent, Gent, Belgium
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-03-04
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 380
- Registration Number
- NCT00140595
- Locations
- 🇧🇪
Groupe d'étude des lymphomes de l'adulte, Yvoir, Belgium
🇫🇷Hôpital Henri Mondor, Créteil, France
🇫🇷Centre Léon Bérard, Lyon, France
Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00141700
- Locations
- 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 223
- Registration Number
- NCT00140660
- Locations
- 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇧🇪Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium
🇨🇭Centre Pluridisciplinaire d'Oncologie, CHUV, Lausanne, Switzerland
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT00137969
- Locations
- 🇺🇸
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 481
- Registration Number
- NCT00137995
- Locations
- 🇮🇱
Israel Society of Hematology, Tel-Hashomer, Israel
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇫🇮Hospital district of south west Finland, Turku, Finland
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00136396
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.